NFE2L2 and acute lymphoblastic leukemia: Gajda et al. demonstrated that inhibiting the MAPK/ERK and PI3K/AKT pathways reduces Nrf2/NF-κΒ levels and prevents drug resistance in REH and MOLT-4 ALL cell lines [193].